Description
FOSCARBIDOPA 12MG/ML/FOSLEVODOPA 240MG/ML INJ,SOLN - 5 MONTH SUPPLY - INCREASE PRICE & USAGE.
Base award description: FOSCARBIDOPA 12MG/ML/FOSLEVODOPA 240MG/ML INJ,SOLN - 4 MONTH SUPPLY
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2025-05-07+$6,865= $6,865
- Mod P000012025-05-21+$61,781= $68,646
- Mod P000022025-08-05+$346= $68,992
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2025-05-07 | +$6,865 | $6,865 | FOSCARBIDOPA 12MG/ML/FOSLEVODOPA 240MG/ML INJ,SOLN - 4 MONTH SUPPLY |
| Mod P00001· FUNDING ONLY ACTION | 2025-05-21 | +$61,781 | $68,646 | FOSCARBIDOPA 12MG/ML/FOSLEVODOPA 240MG/ML INJ,SOLN - 5 MONTH SUPPLY - INCREASE PRICE & USAGE. |
| Mod P00002· FUNDING ONLY ACTION | 2025-08-05 | +$346 | $68,992 | FOSCARBIDOPA 12MG/ML/FOSLEVODOPA 240MG/ML INJ,SOLN - 5 MONTH SUPPLY - INCREASE PRICE & USAGE. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI MAB9Y43Z1US6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26226P0366 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6515 · MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES | $3,317 | FY2026 |
| 36C26226P0330 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6515 · MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES | $1,432 | FY2026 |
| 36C26226P0199 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6515 · MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES | $21,573 | FY2026 |
| 36C26026F0020 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $41,534 | FY2026 |
| 36C26026F0021 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $113,265 | FY2026 |
| 36E79725A0024 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26026F0379 | COSETTE PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $3,466 | FY2026 |
| 36C26026P0671 | MCKESSON PLASMA AND BIOLOGICS LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $18,262 | FY2026 |
| 36C26026F0349 | AGIOS PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $73,080 | FY2026 |
| 36C26026F0306 | BRACCO DIAGNOSTICS INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $337,422 | FY2026 |
| 36C26026F0298 | PROGENICS PHARMACEUTICALS INC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $469,134 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26025F0251_3600_36F79718D0528_3600 · retrieved 2026-09-26.